Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
News
Promising Developments in RNA Interference Therapeutics for Muscular Dystrophy Treatment
Arrowhead Pharmaceuticals Raises $450 Million in Underwritten Offering
Arrowhead Pharmaceuticals* Inducement Grants to Attract Top Talent and Fuel Shareholder Value
Arrowhead Pharmaceuticals Takes Aim at Revolutionizing Kidney Disease Treatment
ARWR Seeks Regulatory Green Light for Groundbreaking RNAi Therapy in Myotonic Dystrophy Treatment
Major Pharmaceutical Preparations Company*s Deficit Widens in Fiscal First Quarter of 2024
Arrowhead Pharmaceuticals Inc Faces Fiscal Disarray as Revenue Plummets
Inspiring information, by the company during the financial interval ending December 31 2022